Tyra Biosciences, Inc.

NasdaqGS:TYRA Stok Raporu

Piyasa değeri: US$2.0b

Tyra Biosciences Yönetim

Yönetim kriter kontrolleri 4/4

Tyra Biosciences CEO'su Todd Harris, Aug2018 tarihinde atandı, in görev süresi 7.75 yıldır. in toplam yıllık tazminatı $ 5.57M olup, şirket hissesi ve opsiyonları dahil olmak üzere 11.8% maaş ve 88.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.28% ine doğrudan sahiptir ve bu hisseler $ 45.39M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 5.8 yıldır.

Anahtar bilgiler

Todd Harris

İcra Kurulu Başkanı

US$5.6m

Toplam tazminat

CEO maaş yüzdesi11.82%
CEO görev süresi7.8yrs
CEO sahipliği2.3%
Yönetim ortalama görev süresi3.9yrs
Yönetim Kurulu ortalama görev süresi5.8yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Oct 01

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Mar 28

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 01

Tyra Biosciences: FGFR1/2 Driven AE Data Spooked The Market

Summary Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated better safety and tolerability compared to erdafitinib, with fewer high-grade toxicities and lower incidence of hyperphosphatemia and other side effects. Financially, Tyra has a market cap of $632mn, a cash balance of $360mn, and a cash runway of 11–20 quarters, depending on expenses. The market's reaction to TYRA-300's data was mixed; further data from the SURF301 trial is needed to make a definitive investment decision. Read the full article on Seeking Alpha
Seeking Alpha • Dec 17

The Take On Tyra Biosciences

Summary Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg. TYRA-300 aims to overcome limitations of existing mUC therapies like Balversa, with ongoing trials at higher 120mg doses and other cancer/genetic indications. Despite safety concerns, analysts remain bullish on Tyra, with unanimous Buy ratings and price targets between $28 and $33 per share. RA Capital Management increased its stake in Tyra, signaling confidence, but the path to first-line therapy approval remains uncertain pending further data. An analysis around Tyra Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha
Analiz Makalesi • Dec 11

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Oct 21

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Key Insights Tyra Biosciences' estimated fair value is US$25.61 based on 2 Stage Free Cash Flow to Equity Tyra...
Seeking Alpha • Oct 21

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Summary Tyra Biosciences will release interim data for its FGFR3-inhibitor TYRA-300 in treating urothelial carcinoma and solid tumors at ENA 2024 on October 25th. Positive interim data could advance TYRA-300 towards a phase 2 study for metastatic urothelial carcinoma and non-muscle invasive bladder cancer patients. TYRA-300 also shows potential for treating skeletal dysplasia disorders, with an IND filing for achondroplasia expected in the second half of 2024. TYRA has a strong cash position, with $373.8 million as of June 30, 2024, sufficient to fund operations into 2026. Read the full article on Seeking Alpha
Analiz Makalesi • Aug 29

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 23

Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences

Summary Tyra Biosciences, Inc. has no revenue or earnings, but share prices have increased by 32.68% in the past year. The company focuses on precision medicines targeting FGFR biology, with future promise in oncology and genetic conditions. Despite bullish signals, the lack of key fundamentals makes Tyra a speculative play, rated as a Hold with potential for growth. Read the full article on Seeking Alpha
Analiz Makalesi • Jul 05

A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Key Insights The projected fair value for Tyra Biosciences is US$18.25 based on 2 Stage Free Cash Flow to Equity Tyra...
Analiz Makalesi • May 13

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Jan 13

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Sep 27

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Jun 13

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tyra Biosciences...
Analiz Makalesi • Feb 23

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analiz Makalesi • Nov 09

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 04

Tyra Biosciences GAAP EPS of -$0.36

Tyra Biosciences press release (NASDAQ:TYRA): Q2 GAAP EPS of -$0.36. As of June 30, 2022, TYRA had cash and cash equivalents of $275.1 million.
Analiz Makalesi • Jul 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Tazminat Analizi

Todd Harris'un ücretlendirmesi Tyra Biosciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$131m

Dec 31 2025US$6mUS$658k

-US$120m

Sep 30 2025n/an/a

-US$112m

Jun 30 2025n/an/a

-US$106m

Mar 31 2025n/an/a

-US$96m

Dec 31 2024US$8mUS$633k

-US$86m

Sep 30 2024n/an/a

-US$84m

Jun 30 2024n/an/a

-US$81m

Mar 31 2024n/an/a

-US$75m

Dec 31 2023US$5mUS$608k

-US$69m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$51m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$2mUS$581k

-US$55m

Sep 30 2022n/an/a

-US$52m

Jun 30 2022n/an/a

-US$46m

Mar 31 2022n/an/a

-US$37m

Dec 31 2021US$6mUS$443k

-US$26m

Sep 30 2021n/an/a

-US$20m

Jun 30 2021n/an/a

-US$16m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$1mUS$350k

-US$9m

Tazminat ve Piyasa: Todd 'ın toplam tazminatı ($USD 5.57M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.35M ).

Tazminat ve Kazançlar: Todd 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Todd Harris (46 yo)

7.8yrs
Görev süresi
US$5,566,997
Tazminat

Dr. Todd Harris, Ph D., co-founded Tyra Biosciences, Inc. and serves as President and Chief Executive Officer since November 2018 and Director since August 2018 and had been its Secretary November 2018 and...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Todd Harris
Co-Founder7.8yrsUS$5.57m2.28%
$ 45.4m
Bhavesh Ashar
Chief Operating Officerless than a yearUS$5.19mVeri yok
Douglas Warner
Chief Medical Officer1.7yrsUS$2.37m0%
$ 0
Daniel Bensen
Co-Founder & Chief Discovery Officer7.8yrsUS$2.66m0.25%
$ 4.9m
Alan Fuhrman
Chief Financial Officer3.3yrsUS$3.53m0.027%
$ 540.0k
Julia Rueb
VP of Finance & Principal Accounting Officerless than a yearVeri yok0.073%
$ 1.4m
Robert Hudkins
Chief Technology Officer5.3yrsVeri yokVeri yok
Ronald Swanson
Chief Scientific Officer6.3yrsUS$2.53mVeri yok
Ali Fawaz
General Counsel & Secretary4yrsUS$2.76mVeri yok
Sarah Honig
Senior VP of Corporate Development & Strategy3.8yrsVeri yokVeri yok
Liz Pagano
Chief Human Resources Officer1.9yrsVeri yokVeri yok
Piyush Patel
Chief Development Officer5.3yrsVeri yokVeri yok
3.9yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş

Deneyimli Yönetim: TYRA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Todd Harris
Co-Founder7.8yrsUS$5.57m2.28%
$ 45.4m
Robert J. More
Independent Director7.5yrsUS$232.67k0%
$ 0
Peter Smith
Scientific Advisorno dataVeri yokVeri yok
Gilla Kaplan
Independent Director7.2yrsUS$197.06k0.047%
$ 943.2k
William Hahn
Scientific Advisorno dataVeri yokVeri yok
Jeffrey Hager
Scientific Advisorno dataVeri yokVeri yok
Rehan Verjee
Independent Director4.9yrsUS$205.57k0%
$ 0
S. Rothenberg
Independent Director2yrsUS$192.47k0%
$ 0
Melissa McCracken
Independent Director5.2yrsVeri yokVeri yok
Jake Simson
Independent Director6.3yrsUS$203.54k0%
$ 0
Susan Moran
Independent Director2yrsUS$203.27k0%
$ 0
Jason Sheltzer
Scientific Advisorno dataVeri yokVeri yok
5.8yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: TYRA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/31 16:08
Gün Sonu Hisse Fiyatı2026/05/29 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Tyra Biosciences, Inc. 19 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Eliana MerleBarclays
Jason ZemanskyBofA Global Research
John NewmanCanaccord Genuity